Abstract:Despite the rapid advancement in the introduction of new drugs for cancer therapy, the frequent emergence of drug resistance leads to disease progression or tumor recurrence resulting in dismal prognosis. Given that genetic mutations are thought to be important drivers of anti-cancer drug resistance, it is of paramount importance to pin-point mutant genes that mediate drug resistance and elucidate the underlying molecular mechanisms in order to develop novel modalities to surmount chemoresistance and achieve more efficacious and durable cancer therapies. Cumulative evidence suggests that epigenetic alterations, especially those mediated by epigenetic enzymes with high mutation rates in cancer patients, can be a crucial factor in the development of chemoresistance. Mutant epigenetic enzymes have altered enzymatic activity which may directly or indirectly affect the level of histone modifications. This can change chromatin structure and function hence altering the expression of target genes and eventually lead to chemoresistance. In the current review, we summarize epigenetic enzyme mutations and the consequent mechanisms of drug resistance in pre-clinical drug-resistance models and relapsed cancer patient specimens. We also introduce previously unreported mutation sites in the DOT1 domain of DOT1L, which are related to lung cancer drug resistance. It is worth noting that mutations occur not only in domains with enzymatic activity but also in non-catalytic regions. Each protein domain is an evolutionarily conserved region with independent functional properties. This may provide a rationale for the potential development of small molecule inhibitors which target various functional domains of epigenetic enzymes. Finally, based on the multitude of mechanisms of drug resistance, we propose several therapeutic strategies to reverse or overcome drug-resistance phenotypes, with the aim to provide cancer patients with novel efficacious combination therapeutic regimens and strategies to improve patient prognosis.

Role and potential therapeutic value of histone methyltransferases in drug resistance mechanisms in lung cancer

Histone methyltransferase and drug resistance in cancers

Lung Cancer Therapy Targeting Histone Methylation: Opportunities and Challenges

Small molecules targeting selected histone methyltransferases (HMTs) for cancer treatment: Current progress and novel strategies

Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance

Epigenetic enzyme mutations as mediators of anti-cancer drug resistance

Novel Insights into Histone Lysine Methyltransferases in Cancer Therapy: from Epigenetic Regulation to Selective Drugs

The role and prospect of lysine-specific demethylases in cancer chemoresistance

Targeting epigenetic regulators to overcome drug resistance in cancers

Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy.

Drug resistance mechanism and reversal strategy in lung cancer immunotherapy

Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer

Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement

Therapeutic targeting of glutamate dehydrogenase 1 that links metabolic reprogramming and Snail-mediated epithelial–mesenchymal transition in drug-resistant lung cancer

Mechanisms of action and resistance in histone methylation-targeted therapy

The role of m6A methylation in therapy resistance in cancer

The role of lncRNA H19 in tumorigenesis and drug resistance of human Cancers

The role of histone methylase and demethylase in antitumor immunity: A new direction for immunotherapy

Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer

The emerging roles of histone demethylases in cancers

Mechanism and Potential Therapeutic Strategies Based on PRMT5 in Chemotherapy-Induced Drug Resistance in Non-Small Cell Lung Cancer